-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Guardant Health, Raises Price Target to $150

Benzinga·06/24/2026 14:38:25
Listen to the news
Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $120 to $150.